Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX06 for prevention of COVID-19 progression in hospitalized non-intubated patients
NL-OMON53826Phase 2Withdrawn
- Sponsor
- F4 Pharma
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing FX06 with Placebo (2 arms). Primary endpoint: Proportion of patients with progressed or worsened disease state by day 28. Planned start Jul 2022; status: withdrawn.
02
Drugs
FX06
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON53826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53826.